4//SEC Filing
Fok Manson 4
Accession 0001209191-23-025401
CIK 0001300699other
Filed
Apr 23, 8:00 PM ET
Accepted
Apr 24, 4:36 PM ET
Size
25.4 KB
Accession
0001209191-23-025401
Insider Transaction Report
Form 4
Athenex, Inc.ATNX
Fok Manson
Director
Transactions
- Award
Common Stock
2023-04-21$1.30/sh+5,747$7,500→ 110,675 total
Holdings
- 33,944(indirect: By Avalon Biomedical (Management) Limited)
Common Stock
- 2,400
Stock Option (Right to Buy)
Exercise: $91.00From: 2014-05-13Exp: 2023-05-13→ Common Stock (2,400 underlying) - 2,000
Stock Option (Right to Buy)
Exercise: $91.00From: 2016-06-12Exp: 2024-06-12→ Common Stock (2,000 underlying) - 500
Stock Option (Right to Buy)
Exercise: $249.00Exp: 2030-06-05→ Common Stock (500 underlying) - 5,360(indirect: By Avalon Polytom (HK) Limited)
Common Stock
- 1,000
Stock Option (Right to Buy)
Exercise: $91.00From: 2015-10-11Exp: 2023-10-11→ Common Stock (1,000 underlying) - 2,400
Stock Option (Right to Buy)
Exercise: $180.00From: 2017-10-17Exp: 2025-10-17→ Common Stock (2,400 underlying) - 2,746(indirect: By Avalon Biomedical (Management) Limited)
Stock Option (Right to Buy)
Exercise: $180.00From: 2018-07-17Exp: 2025-07-17→ Common Stock (2,746 underlying) - 2,400
Stock Option (Right to Buy)
Exercise: $150.00From: 2016-05-18Exp: 2025-05-18→ Common Stock (2,400 underlying) - 1,350
Stock Option (Right to Buy)
Exercise: $220.00From: 2021-06-13Exp: 2027-06-13→ Common Stock (1,350 underlying) - 313
Stock Option (Right to Buy)
Exercise: $76.00From: 2022-08-03Exp: 2031-08-03→ Common Stock (313 underlying) - 750
Stock Option (Right to Buy)
Exercise: $346.00From: 2022-03-27Exp: 2028-03-27→ Common Stock (750 underlying) - 500
Stock Option (Right to Buy)
Exercise: $263.40From: 2023-02-28Exp: 2029-02-28→ Common Stock (500 underlying) - 625
Stock Option (Right to Buy)
Exercise: $9.14Exp: 2032-06-28→ Common Stock (625 underlying)
Footnotes (8)
- [F1]Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
- [F2]As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
- [F3]Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
- [F4]Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F5]These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
- [F6]This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
- [F7]This option vests in four equal annual installments beginning on June 5, 2021.
- [F8]This option vests on June 28, 2023.
Documents
Issuer
Athenex, Inc.
CIK 0001300699
Entity typeother
Related Parties
1- filerCIK 0001708964
Filing Metadata
- Form type
- 4
- Filed
- Apr 23, 8:00 PM ET
- Accepted
- Apr 24, 4:36 PM ET
- Size
- 25.4 KB